19 studies on CJC-1295 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 1,100 published CJC-1295 COA source records from third-party laboratories, covering 397 publicly attributable vendor identities. Across 984 records with positive numeric purity, the arithmetic mean is 97.8%. 39 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 60 positive purity results are below 90%; 146 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-15. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-15. Aggregate calculated: 2026-10-18T04:28:50.414859+00:00. Calculation time is not a laboratory observation date.
Within that total, 182 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 19 | 98.98% | 0 of 19 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 15 | 99.61% | 0 of 15 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 14 | 97.06% | 0 of 13 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #119828 (90.8%) · #119414 (99.08%) · #119529 (99.9%) · #120216 (99.43%) · #119670 (99.6%) · #118629 (99.21%)
**Clinicians and peptide users combining GHS with GHRH analogs** (e.g., sermorelin or CJC-1295) should note the synergistic GH release depends entirely on hypothalamo-pituitary integrity — individuals with hypothalami…
**GH secretagogues represent a potentially superior alternative to exogenous GH** for older adults or clinicians pursuing somatotropic support, because they work through the body's own pulse-generation machinery rathe…
**CJC-1295's ability to bioconjugate to endogenous albumin in vivo after a single subcutaneous dose** fundamentally changes the pharmacokinetic calculus for GRF-based therapies — a single injection may sustain GH axis…
**Weekly or biweekly dosing** replacing daily GHRH injections is a substantial practical advance for any GH-optimization protocol. Clinicians and researchers investigating GH axis restoration — whether for **GH defici…
**Dosing frequency is the decisive variable** for CJC-1295 efficacy — every-24-hour administration is the threshold at which full growth rescue occurs in this model, while every-48-hour dosing yields only partial bene…
**Continuous GHRH stimulation does not blunt GH pulsatility** — a concern that had been a theoretical barrier to long-acting GHRH therapeutics. For clinicians and researchers, this validates the mechanistic rationale …
**Identifying reliable serum biomarkers of GH action is a critical unmet need** both for anti-doping enforcement and for titrating GH replacement therapy in clinical practice. The linear IGF-1 correlation with the imm…
The identification of CJC-1295 in an illicit preparation highlights the ongoing challenge of unregulated peptide drug availability and use, particularly within communities like bodybuilding. As a growth hormone-releas…
This new comprehensive testing protocol represents a significant upgrade for anti-doping agencies. By enabling the simultaneous screening of numerous peptides like CJC-1295, insulins, and growth factors in a single ru…
This research highlights a specific area of off-label, self-directed drug use that is largely unmonitored by healthcare professionals. For clinicians and public health officials, it underscores the need to be aware th…
This highly sensitive detection method provides sports anti-doping agencies with a powerful new tool for identifying the use of prohibited GHRHs like CJC-1295. For athletes and individuals using these peptides, this s…
This `I-PCR` assay represents a significant leap forward for anti-doping in equine sports and potentially beyond. Standard mass spectrometry methods are blind to CJC-1295 once it binds to plasma proteins, creating a m…
This groundbreaking method provides a definitive and highly sensitive tool for anti-doping agencies to confirm the illicit use of CJC-1295 in equestrian sports. The ability to detect conjugated CJC-1295, which has a p…
This research provides anti-doping laboratories with a validated, highly sensitive protocol for detecting **CJC-1295** and similar banned peptides. For athletes using these substances, this significantly increases the…
This study represents a significant advancement in the fight against doping in sports, specifically targeting growth hormone releasing hormone synthetic analogs. By identifying and characterizing previously unknown me…
For athletes and individuals using performance-enhancing peptides, this review underscores that sophisticated detection methods are already established for a wide array of compounds, including popular research peptide…
This hypothetical study highlights CJC-1295's potential as a long-acting growth hormone-releasing hormone (GHRH) analog, capable of providing sustained GH and IGF-1 elevation from a single dose. This sustained release…
The premature termination of this Phase 2 study signifies that the potential of CJC 1295 as a viable treatment for HIV-associated visceral obesity remains entirely unconfirmed and unexplored through the completion of …
Free, no account — handy when you're working with CJC-1295.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account